Telomir Pharmaceuticals (TELO)
Develops an oral small-molecule candidate for advanced triple-negative breast cancer.
Something off on this page? Send us feedback.
Develops Telomir-Zn, an oral small-molecule candidate for advanced or metastatic triple-negative breast cancer. With no commercial products or operating revenue, progress depends on clinical development, regulatory approval, licensed intellectual property, and outsourced research and manufacturing.
Develops Telomir-Zn, also known as Telomir-1, an orally administered small molecule whose current lead use is advanced or metastatic triple-negative breast cancer. The FDA cleared an IND for a planned multicenter oral-monotherapy clinical study, while the latest public registry update listed the trial as not yet recruiting. Research also covers Wilson's disease, diabetes, Progeria, age-related macular degeneration, and other cancer and age-related conditions.
Operates from a virtual Miami office without full-time employees, relying on consultants and third parties for scientific work and manufacturing. With no approved products or operating revenue, development and commercialization depend on clinical progress, regulatory approval, and licensed intellectual property. MIRALOGX owns the underlying intellectual property and controls patent prosecution.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.2M · Total debt $0 · Total assets $5.4M · Shareholders' equity $5.0M
- Revenue
- $0
- Operating income
- −$1.8M
- Net income
- −$1.7M
No dividends on record.
| Institutions27 holders · as of Mar 31, 2026 | 3.26% | 2.24M shares | |
| Insiders1 holder · as of Apr 24, 2026 | 10.64% | 7.32M shares | |
| Strategic holders1 holder · as of Oct 3, 2025 | 5.12% | 3.52M shares | |
| Otherremainder | 80.98% | 55.69M shares |
68.77M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Erez AminovInsiderdirector, officer: CEO and Chairman | 10.64% | 7.32M | Form 4filed Apr 24, 2026 ↗ |
Mira Pharmaceuticals, Inc.Strategic10 percent owner | 5.12% | 3.52M | Form 4filed Oct 3, 2025 ↗ |
Vanguard Capital Management LLCInstitution | 1.45% | 995,373 | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 0.42% | 289,198 | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.36% | 249,086 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Gilead Sciences
Approved TNBC ADC with first-line and later-line coverage.
- Merck
PD-1 regimen for PD-L1-positive first-line advanced TNBC.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Telomir Pharmaceuticals | $1.13 | +2.73% | $77.0M | — | — | — | — |
| Gilead Sciences | $149.20 | −0.27% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Merck | $151.14 | −0.33% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Median | 121.3 | 17.0 | 5.9 | +7.6% |